Connect Biopharma Holdings Limited

Stage 4 · Declining · week 6

As of Oct 22, 2026, Connect Biopharma Holdings is in Stage 4, the downtrend phase, now in week 6 (since Sep 16, 2026). It closed at $0.76, 79.3% below its 52-week high and below its 200-day average, which is falling.

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. More about the company

$0.76

-3.62% today

$48.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CNTB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 17w

S4 29w

S2 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 2w → S4 8w → S1 3w → S2 8w → S3 4w → S4 3w → S3 1w → S2 17w → S3 7w → S4 8w → S1 5w → S4 29w → S1 5w → S2 11w → S3 6w → S2 14w → S3 1w → S2 10w → S3 7w → S4 8w → S1 3w → S4 5w current

Total tracked: 165 weeks across 22 stage runs.

CNTB among Biotechnology378th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…378	CNTBConnect Biopharma Holdings Limited	Stage 4 · wk 6	21	−28.8%

vs 52W High

-79.3%

$0.76 lo$3.69 hi

79.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-65.9%

200 DMA: $2.24 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.22x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-28.8%

-64.4%

-69.8%

YTD

-69.8%

-54.9%

Scan Membership

Breakout Watch

Latest: 2026-03-05

7 appearances in last 60 days. First seen: 2023-02-22.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 0.22x

2026-10-21S4

Wk 6 · Vol 0.32x

2026-10-20S4

Wk 5 · Vol 0.07x

2026-10-19S4

Wk 5 · Vol 0.21x

2026-10-16S4

Wk 5 · Vol 0.12x

2026-10-15S4

Wk 5 · Vol 0.31x

2026-10-14S4

Wk 5 · Vol 0.23x

2026-10-13S4

Wk 4 · Vol 0.37x

2026-10-12S4

Wk 4 · Vol 0.34x

2026-10-09S4

Wk 4 · Vol 0.22x

2026-10-08S4

Wk 4 · Vol 0.26x

2026-10-07S4

Wk 4 · Vol 0.26x

Moving averages & range

50 DMA

$1.56

200 DMA

$2.24

52W High

$3.69

52W Low

$0.76

5D Low

$0.76

Resistance levels (recent highs)

20d High

$1.10

60d High

$2.76

120d High

$2.76

250d High

$3.69

Next resistance

+44.4%

to 20d High

ROE

-140.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.8

Connect Biopharma Holdings: quick answers

What stage is Connect Biopharma Holdings in?

As of Oct 22, 2026, Connect Biopharma Holdings (CNTB) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 16, 2026 and is in week 6. What the four stages mean

Is Connect Biopharma Holdings in an uptrend?

No. Connect Biopharma Holdings is in a Stage 4 downtrend. It trades 65.9% below its 200-day average, which is falling.

How far is Connect Biopharma Holdings from its 52-week high?

Connect Biopharma Holdings closed at $0.76 on Oct 22, 2026, 79.3% below its 52-week high of $3.69. Its 52-week low is $0.76.

How has Connect Biopharma Holdings performed over the past year?

As of Oct 22, 2026, Connect Biopharma Holdings is down 54.9% over the past year and down 69.8% so far in 2026.

Which sector and industry is Connect Biopharma Holdings in?

Connect Biopharma Holdings is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.